Article

Faricimab provides sustained retinal stability in DME

Author(s):

Veeral Sheth, MD, presents research finding faricimab, a bispecific monoclonal antibody, provided sustained retinal stability in patients with diabetic macular edema (DME) compared with other retinal treatments.

Faricimab provides sustained retinal stability in DME

In a study, outlined at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Veeral Sheth, MD, and colleagues reported that faricimab, a bispecific monoclonal antibody, provided sustained retinal stability in patients with diabetic macular edema (DME) compared with other retinal treatments.

In preclinical studies, blocking angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF-A) reduced the vascular leakage/neovascularization, inflammation, and fibrosis.

In a phase 2 post hoc analyses, the investigators assessed, in the intention-to-treat population, the sustained retinal stability, defined as occurrence and less than 10% worsening of the central subfield to 325 microns or less to week 24.

The inflammatory biomarker, intercellular adhesion molecule-1 (ICAM-1), levels also were assessed in a patient subset from baseline to week 28.

The investigators reported that more than 50% of patients achieved sustained retinal stability at weeks 8 and 16 with faricimab compared with week 20 with ranibizumab (Lucentis, Genentech).

At week 28, the mean percentage of the ICAM-1 levels compared with baseline increased by 50% with ranibizumab and decreased by 56% and 42% in the 2 faricimab arms.

The investigators concluded that faricimab resulted in sustained retinal stability and ICAM-1 reduction compared with ranibizumab in the phase 2 study.

In addition, in the phase 3 studies, faricimab showed greater anatomic improvement compared with aflibercept (Eyelea, Regeneron) and potential for improved durability due to vascular stability by Ang-2 inhibition.

Faricimab is the only medicine targeting two distinct pathways, Ang-2 and VEGF-A, that often cause retinal diseases that may cause vision loss.

See more AAO meeting coverage

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.